Dr. Deborah Assayag and her team, led by Dr. DAvid Langlais, received D2R funding from their Clinical Research and Development program. This program supports research that strategically leverages the context of existing or ongoing clinical trials involving RNA therapeutic.
About the project: Interstitial lung disease (ILD) is a serious complication of autoimmune diseases that causes lung scarring, breathing problems, and reduced lifespan. Current treatments are often ineffective because ILD is rare and highly variable between patients. Our research aims to identify simple blood-based markers that can help diagnose ILD earlier and guide more personalized treatments. We are testing whether a specific immune cell marker can predict which patients will benefit from a medication called rituximab. By combining clinical data with advanced genetic and protein analysis, we aim to improve care for people with ILD and develop better, individualized therapies.
Read More
D2R Clinical Research and Development (CRD) funding program. November 26, 2025 D2R Newsletter